At the news
? BEARISHIMPACT 7/10 424B5 filed Apr 15, 2026 at 17:24 ET
Revolution Medicines is raising $500 million through a 0.50% convertible senior notes offering due 2033, with an additional concurrent $1.4 billion common stock offering. The notes offer a low interest rate and conversion into equity if the stock price exceeds 130% of the conversion price, but carry significant dilution risk and subordination in the capital structure.
- Company is offering $500 million in 0.50% convertible senior notes due 2033
- Concurrent common stock offering of $1.435 billion (up to $1.65 billion if option exercised)
- Initial conversion price of $198.80 per share, representing a 35% premium to current stock price of $147.01
- Notes are senior unsecured obligations, structurally subordinated to subsidiary liabilities
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access